Loading
Intellia Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Cohen Fred E, was filed 07 Jan 2026.
Insider Decl.
514
Thresholds
n/a
Buy Volume
€18M
10 ops. · all time
Sell Volume
€262M
286 ops. · all time
Who traded when
BuySaleJohn M. Leonard7 sales
Eliana Clark6 sales
Michael P. Dube6 sales
Edward J. Dulac III4 sales
James Basta4 sales
Birgit C. Schultes2 sales
+7 other insiders
Since the insiders bought
- +12.5%Entry US$10.52 · Close 20 Oct 2026 US$11.84
- +10.4%Entry US$11.38 · Close at T+365 US$12.56
- -33.3%Entry US$16.49 · Close at T+365 US$11.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Intellia Therapeutics, Inc. Buy (bullish), based on 18 analysts. Average price target: US$23.11.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$11.84
Analyst consensus
18 analystsBuy
US$8.00Target US$23.11(+95%)US$61.00
Income statement
RevenueUS$67.7M
EBITDA-US$425.1M-628% margin
Net income-US$412.7M-609.9% margin
Valuation
PER (forward)-4.6x
P/Book2.3x
Beta1.80
Balance sheet & cash
Market capUS$1.7B
Total debtUS$93.3M
Free Cash Flow-US$395.9M
Debt / Equity10%
Profitability & ownership
ROE-55.4%
ROA-30.1%
% insiders3.8%
% institutions100.1%
Last declaration on 6 October 2026
Declarations514 total
1,864 shares@ US$12.430.0013% mcap11.3% of flowCommon StockSEC:0001193125-26-415541:0
57,750 shares@ US$12.750.043% mcap100.0% of flowCommonSEC144:0001950047-26-010054
19,890 shares@ US$12.600.014% mcap7.6% of flowCommon StockSEC:0001193125-26-363567:0
2,785 shares@ US$13.000.0020% mcap1.1% of flowCommon StockSEC:0001193125-26-363567:1
22,675 shares@ US$12.950.017% mcap8.9% of flowCommonSEC144:0001969223-26-000938
8,111 shares@ US$11.250.0053% mcap27.3% of flowCommon StockSEC:0001193125-26-316279:0
2,641 shares@ US$16.780.0026% mcap24.0% of flowCommon StockSEC:0002019493-26-000002:0
4,677 shares@ US$18.000.0049% mcap25.2% of flowCommon StockSEC:0001821530-26-000002:0
4,677 shares@ US$17.240.0046% mcap100.0% of flowCOMMONSEC144:0001950047-26-006836
9,200 sharesCommon StockSEC:0001193125-26-266236:0
9,200 sharesCommon StockSEC:0001193125-26-266230:0
9,200 sharesCommon StockSEC:0001563572-26-000001:0
9,200 sharesCommon StockSEC:0001193125-26-266233:0
9,200 sharesCommon StockSEC:0001756929-26-000002:0
607 shares@ US$13.781.0% of flowCommon StockSEC:0001193125-26-088241:1
1,211 shares@ US$13.783.1% of flowCommon StockSEC:0001193125-26-088260:1
156,400 shares0Common StockSEC:0001193125-26-088269:0
46,080 shares0Common StockSEC:0001193125-26-088260:0
9,943 shares0Common StockSEC:0001193125-26-088258:0
61,280 shares0Common StockSEC:0001193125-26-088254:0
39,200 shares0Common StockSEC:0001193125-26-088251:0
7,353 shares0Common StockSEC:0001193125-26-088241:0
17,250 shares0Common StockSEC:0001193125-26-088236:0
2,989 shares@ US$9.2114.5% of flowCommon StockSEC:0001193125-26-006264:0
34,146 shares@ US$9.219.5% of flowCommon StockSEC:0001193125-26-006294:0
25 of 514 declarations
About Intellia Therapeutics, Inc.
On May 11, 2016, the day of Intellia Therapeutics, Inc.'s first filing, 5 filers bought EUR 20,127,748: Temasek Holdings (Private) Ltd (10% Owner) EUR 4,725,648, Novartis Institutes for BioMedical Research, Inc. (10% Owner) EUR 4,375,588 and Orbimed Advisors LLC (Director) EUR 3,016,003. Across the full history, 8 purchase filings are classed as clustered. The record's 12 purchases total EUR 22.3 million, with a median of EUR 1,060,138, or 4% of open-market trades.
The 286 sales weigh EUR 261.6 million, with a median of EUR 143,867. The largest: Jean Francois Formela (Director), EUR 24,885,870 on February 26, 2021; Novartis Institutes for BioMedical Research, Inc., EUR 23,664,346 on December 12, 2017; Caribou Biosciences, Inc. (10% Owner), EUR 11,865,294 on January 29, 2018. Formela signs 52 filings, 46 of them sales.
Read moreShow less
John M. Leonard, President and CEO, is the most frequent filer, with 102 filings, 59 of them sales; Jose E. Rivera (EVP, General Counsel) signs 68, with 47. The record holds 514 filings from May 11, 2016 to October 6, 2026, 216 of them in 2021 alone, against 3 in 2019. There are 95 grants and 93 option exercises. The US healthcare and pharma company is worth USD 1.66 billion, with 3.8% held by insiders. Last twelve months: 36 filings, 1 purchase, 18 sales. For the 12 purchases with a result, the 90-day median is -23.9%, with 8% of results positive (recorded past, not a forecast).
